Christine Cotton Preservation archive
English Français

← All interviews · All research follow-ups →

COVID : les vérités cachées de la politique vaccinale - Christine Cotton

Ligne Droite • La matinale de Radio Courtoisie · YouTube · Watch ▶

📅 2023-06-08🎙️ Valentin Tomas (host) with Didier Maïsto (Thursday co-host)📺 Radio Courtoisie — Ligne droite, la matinale⏱ 42 min
“I have been making this claim for a year and a half. I have had no lawsuit, and not a single person in the world has managed to produce the slightest argument that my analysis is wrong.”

Key statements

  • Pfizer CEO Albert Bourla himself has acknowledged the mRNA technology had never previously been used in a marketed vaccine or medicine. Authorizing it in 9 months for a new disease drove much of the public's vaccine hesitancy. ▶ 04:50
    Sources: Albert Bourla — public statements / Pfizer interviews
  • Didier Maïsto enumerates the registration gaps from Cotton's report: severe adverse events not studied; follow-up too short; high-risk populations not studied; transmission, asymptomatic infection, mortality, co-infections, virus evolution, duration of protection, antibody waning — all left unstudied. ▶ 07:03
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • Cotton uses the phrase "experts without expertise" for the medical figures on TV during the crisis: most never wrote a protocol or actively contributed to a clinical trial — and none of them is a biostatistician. ▶ 08:04
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • The 95% figure is a ratio computed on 8 vs 162 PCR-confirmed symptomatic cases. As an absolute-risk difference, the same numbers yield 0.84% — and the underlying endpoint counts only mild or moderate PCR-confirmed COVID seven days after dose 2. ▶ 11:52
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Every COVID-vaccine authorization relied on an interim analysis: a study designed to last two years was decided on three months of follow-up, with half of participants followed less than two months. ▶ 12:53
    Sources: Pfizer C4591001 Protocol; Pfizer C4591001 interim clinical study report (Dec 2020)
  • Because of the methodological flaws, the benefit-risk ratio announced by Pfizer and accepted by regulators is false, full stop. Despite 18 months making this claim publicly, Cotton has faced no lawsuit and no one in the world has rebutted her analysis. ▶ 15:03
    Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
  • After Cotton posted her January 2022 expertise on LinkedIn, 133 lawyers visited her profile within two days — before LinkedIn closed her account on the pretext that she was sharing false information. ▶ 15:12
    Sources: Cotton — January 2022 expertise report (LinkedIn post, screenshots)
  • Maddie de Garay enrolled with her two siblings in the 12-15 trial; she suffered more than 30 serious adverse events with permanent disability and is now in a wheelchair with a gastric tube. Two effects vaguely appear in the clinical report; nothing reflects the gravity of her case. ▶ 18:21
    Sources: Maddie de Garay testimony to Sen. Ron Johnson; Pfizer C4591001 (12-15 yrs) clinical study report
  • Brianne Dressen (AstraZeneca trial, US) alerted for months about severe neurological effects she suffered during the trial. Health authorities worldwide systematically refused to listen to trial-arm participants reporting that they were nearly killed by the vaccine. ▶ 19:49
    Sources: Brianne Dressen — public testimony (REACT19, US Senate)
  • Europe's EMA database holds about 1.2 million adverse-event reports for COVID vaccines. With reporting estimated between 1% and 10%, the underlying incidence is somewhere between 12 million and 120 million cases — myocarditis and pericarditis are among the few signals officially recognized. ▶ 27:09
    Sources: EudraVigilance / EMA adverse-event database
  • In December 2020 there was no statistically demonstrated efficacy in the over-75 subgroup and no demonstrated effect on severe cases. Vaccinating the over-75s — those most affected by COVID mortality — was therefore done in the absence of trial-based evidence. ▶ 30:49
    Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
  • Cotton describes her in-camera testimony to OPECST and the June 2022 written report that followed: the parliamentary office wrote that victims should be recognized and supported. A final version was promised for autumn 2022 — and is still pending at the time of recording. ▶ 39:49
    Sources: OPECST report on COVID-19 vaccine adverse events (June 2022 draft)

Documents cited

  • Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com
  • Cotton — book Tous vaccinés, tous protégés ? (Guy Trédaniel, 2023) — Guy Trédaniel éditeur
  • Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
  • Pfizer C4591001 (12-15 yrs) clinical study report — FDA / EMA submission archives
  • Comirnaty Risk Management Plan (December 2020, EMA) — EMA EPAR archive
  • EudraVigilance / EMA adverse-event database — adrreports.eu
  • ANSM pharmacovigilance reports — ansm.sante.fr
  • OPECST report on COVID-19 vaccine adverse events (June 2022 draft) — Assemblée nationale / Sénat archive
  • Maddie de Garay testimony to Sen. Ron Johnson — Sen. Ron Johnson public events
  • Brianne Dressen — public testimony — REACT19, US Senate hearings
  • Albert Bourla — public statements / Pfizer interviews — Pfizer press materials

Research follow-ups

All research follow-ups →